Edward P. Retzbach

机构：Johnson & Johnson (United States), Springhouse, Innovative Clinical Research, Innovative Research (United States) · ORCID：0000-0003-4615-8850

发表论文 18 篇 · 总被引 520 次 · h-index 10

代表论文

• Podoplanin: An emerging cancer biomarker and therapeutic target (2018 · Cancer Science · 被引 199)
• Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms (2015 · Oncotarget · 被引 87)
• Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target (2018 · Oral Oncology · 被引 50)
• Components in aqueous Hibiscus rosa-sinensis flower extract inhibit in vitro melanoma cell growth (2016 · Journal of Traditional and Complementary Medicine · 被引 40)
• PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility (2015 · Experimental Cell Research · 被引 29)
• Effects of Maackia amurensis seed lectin (MASL) on oral squamous cell carcinoma (OSCC) gene expression and transcriptional signaling pathways (2020 · Journal of Cancer Research and Clinical Oncology · 被引 27)